A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer

Andres Rojas, Pingyu Zhang, Ying Wang, Wai Chin Foo, Nina M. Muñoz, Lianchun Xiao, Jing Wang, Gregory James Gores, Mien Chie Hung, Boris Blechacz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is globally the second most common cause of cancer mortality. The majority of HCC patients are diagnosed at advanced stage disease for which no curative treatments exist. TGF-β has been identified as a potential therapeutic target. However, the molecular mechanisms mediating its functional switch from a tumor suppressor to tumor promoter in HCC and its interactions with other signaling pathways are poorly understood. Here, we demonstrate an aberrant molecular network between the TGF-β and c-KIT pathway that mediates the functional switch of TGF-β to a driver of tumor progression in HCC. TGF-β/SMAD2 signaling transcriptionally regulates expression of the c-KIT receptor ligand (stem cell factor [SCF]) with subsequent auto- and paracrine activation of c-KIT/JAK1/STAT3 signaling. SCF induces TGF-β1 ligand expression via STAT3, thereby forming a positive feedback loop between TGF-β/SMAD and SCF/c-KIT signaling. This network neutralizes TGF-β–mediated cell cycle inhibition and induces tumor cell proliferation, epithelial-to-mesenchymal-transition, migration, and invasion. Disruption of this feedback loop inhibits TGF-β tumor-promoting effects and restores its antiproliferative functions. Consistent with our in vitro data, we demonstrate SCF overexpression and its correlation to SMAD2 and STAT3 activation in human HCC tumors, advanced tumor-node-metastasis stages, and shorter survival. CONCLUSIONS: Canonical TGF-β and c-KIT signaling forms a positive, tumor-promoting feedback loop. Disruption of this loop restores TGF-β tumor suppressor function and provides the rationale for targeting the TGF-β/SCF axis as a novel therapeutic strategy for HCC.

Original languageEnglish (US)
Pages (from-to)371-386
Number of pages16
JournalNeoplasia (United States)
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Stem Cell Factor
Neoplasms
Proto-Oncogene Proteins c-kit
Ligands
Epithelial-Mesenchymal Transition
Carcinogens
Cell Cycle
Therapeutics
Cell Proliferation
Neoplasm Metastasis
Survival
Mortality

ASJC Scopus subject areas

  • Cancer Research

Cite this

Rojas, A., Zhang, P., Wang, Y., Foo, W. C., Muñoz, N. M., Xiao, L., ... Blechacz, B. (2016). A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. Neoplasia (United States), 18(6), 371-386. https://doi.org/10.1016/j.neo.2016.04.002

A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. / Rojas, Andres; Zhang, Pingyu; Wang, Ying; Foo, Wai Chin; Muñoz, Nina M.; Xiao, Lianchun; Wang, Jing; Gores, Gregory James; Hung, Mien Chie; Blechacz, Boris.

In: Neoplasia (United States), Vol. 18, No. 6, 01.06.2016, p. 371-386.

Research output: Contribution to journalArticle

Rojas, A, Zhang, P, Wang, Y, Foo, WC, Muñoz, NM, Xiao, L, Wang, J, Gores, GJ, Hung, MC & Blechacz, B 2016, 'A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer', Neoplasia (United States), vol. 18, no. 6, pp. 371-386. https://doi.org/10.1016/j.neo.2016.04.002
Rojas, Andres ; Zhang, Pingyu ; Wang, Ying ; Foo, Wai Chin ; Muñoz, Nina M. ; Xiao, Lianchun ; Wang, Jing ; Gores, Gregory James ; Hung, Mien Chie ; Blechacz, Boris. / A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. In: Neoplasia (United States). 2016 ; Vol. 18, No. 6. pp. 371-386.
@article{57b6b6f00bef45e792602253b073be4a,
title = "A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer",
abstract = "Hepatocellular carcinoma (HCC) is globally the second most common cause of cancer mortality. The majority of HCC patients are diagnosed at advanced stage disease for which no curative treatments exist. TGF-β has been identified as a potential therapeutic target. However, the molecular mechanisms mediating its functional switch from a tumor suppressor to tumor promoter in HCC and its interactions with other signaling pathways are poorly understood. Here, we demonstrate an aberrant molecular network between the TGF-β and c-KIT pathway that mediates the functional switch of TGF-β to a driver of tumor progression in HCC. TGF-β/SMAD2 signaling transcriptionally regulates expression of the c-KIT receptor ligand (stem cell factor [SCF]) with subsequent auto- and paracrine activation of c-KIT/JAK1/STAT3 signaling. SCF induces TGF-β1 ligand expression via STAT3, thereby forming a positive feedback loop between TGF-β/SMAD and SCF/c-KIT signaling. This network neutralizes TGF-β–mediated cell cycle inhibition and induces tumor cell proliferation, epithelial-to-mesenchymal-transition, migration, and invasion. Disruption of this feedback loop inhibits TGF-β tumor-promoting effects and restores its antiproliferative functions. Consistent with our in vitro data, we demonstrate SCF overexpression and its correlation to SMAD2 and STAT3 activation in human HCC tumors, advanced tumor-node-metastasis stages, and shorter survival. CONCLUSIONS: Canonical TGF-β and c-KIT signaling forms a positive, tumor-promoting feedback loop. Disruption of this loop restores TGF-β tumor suppressor function and provides the rationale for targeting the TGF-β/SCF axis as a novel therapeutic strategy for HCC.",
author = "Andres Rojas and Pingyu Zhang and Ying Wang and Foo, {Wai Chin} and Mu{\~n}oz, {Nina M.} and Lianchun Xiao and Jing Wang and Gores, {Gregory James} and Hung, {Mien Chie} and Boris Blechacz",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.neo.2016.04.002",
language = "English (US)",
volume = "18",
pages = "371--386",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer

AU - Rojas, Andres

AU - Zhang, Pingyu

AU - Wang, Ying

AU - Foo, Wai Chin

AU - Muñoz, Nina M.

AU - Xiao, Lianchun

AU - Wang, Jing

AU - Gores, Gregory James

AU - Hung, Mien Chie

AU - Blechacz, Boris

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Hepatocellular carcinoma (HCC) is globally the second most common cause of cancer mortality. The majority of HCC patients are diagnosed at advanced stage disease for which no curative treatments exist. TGF-β has been identified as a potential therapeutic target. However, the molecular mechanisms mediating its functional switch from a tumor suppressor to tumor promoter in HCC and its interactions with other signaling pathways are poorly understood. Here, we demonstrate an aberrant molecular network between the TGF-β and c-KIT pathway that mediates the functional switch of TGF-β to a driver of tumor progression in HCC. TGF-β/SMAD2 signaling transcriptionally regulates expression of the c-KIT receptor ligand (stem cell factor [SCF]) with subsequent auto- and paracrine activation of c-KIT/JAK1/STAT3 signaling. SCF induces TGF-β1 ligand expression via STAT3, thereby forming a positive feedback loop between TGF-β/SMAD and SCF/c-KIT signaling. This network neutralizes TGF-β–mediated cell cycle inhibition and induces tumor cell proliferation, epithelial-to-mesenchymal-transition, migration, and invasion. Disruption of this feedback loop inhibits TGF-β tumor-promoting effects and restores its antiproliferative functions. Consistent with our in vitro data, we demonstrate SCF overexpression and its correlation to SMAD2 and STAT3 activation in human HCC tumors, advanced tumor-node-metastasis stages, and shorter survival. CONCLUSIONS: Canonical TGF-β and c-KIT signaling forms a positive, tumor-promoting feedback loop. Disruption of this loop restores TGF-β tumor suppressor function and provides the rationale for targeting the TGF-β/SCF axis as a novel therapeutic strategy for HCC.

AB - Hepatocellular carcinoma (HCC) is globally the second most common cause of cancer mortality. The majority of HCC patients are diagnosed at advanced stage disease for which no curative treatments exist. TGF-β has been identified as a potential therapeutic target. However, the molecular mechanisms mediating its functional switch from a tumor suppressor to tumor promoter in HCC and its interactions with other signaling pathways are poorly understood. Here, we demonstrate an aberrant molecular network between the TGF-β and c-KIT pathway that mediates the functional switch of TGF-β to a driver of tumor progression in HCC. TGF-β/SMAD2 signaling transcriptionally regulates expression of the c-KIT receptor ligand (stem cell factor [SCF]) with subsequent auto- and paracrine activation of c-KIT/JAK1/STAT3 signaling. SCF induces TGF-β1 ligand expression via STAT3, thereby forming a positive feedback loop between TGF-β/SMAD and SCF/c-KIT signaling. This network neutralizes TGF-β–mediated cell cycle inhibition and induces tumor cell proliferation, epithelial-to-mesenchymal-transition, migration, and invasion. Disruption of this feedback loop inhibits TGF-β tumor-promoting effects and restores its antiproliferative functions. Consistent with our in vitro data, we demonstrate SCF overexpression and its correlation to SMAD2 and STAT3 activation in human HCC tumors, advanced tumor-node-metastasis stages, and shorter survival. CONCLUSIONS: Canonical TGF-β and c-KIT signaling forms a positive, tumor-promoting feedback loop. Disruption of this loop restores TGF-β tumor suppressor function and provides the rationale for targeting the TGF-β/SCF axis as a novel therapeutic strategy for HCC.

UR - http://www.scopus.com/inward/record.url?scp=85010824762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010824762&partnerID=8YFLogxK

U2 - 10.1016/j.neo.2016.04.002

DO - 10.1016/j.neo.2016.04.002

M3 - Article

C2 - 27292026

AN - SCOPUS:85010824762

VL - 18

SP - 371

EP - 386

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 6

ER -